<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04994457</url>
  </required_header>
  <id_info>
    <org_study_id>20210472</org_study_id>
    <nct_id>NCT04994457</nct_id>
  </id_info>
  <brief_title>Patient Performance on Virtual Reality Visual Field Devices as Compared to Standard of Care</brief_title>
  <official_title>Patient Performance on Virtual Reality Visual Field Devices as Compared to Standard of Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to study the effectiveness and patient experience when&#xD;
      measuring visual fields using virtual reality goggles.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of VRVF compared to SAP</measure>
    <time_frame>Day 1</time_frame>
    <description>Sensitivity of VRVF will be determined by comparing Hodapp Anderson Parrish (HAP) Scores, which assess the severity of visual field defects, to those of SAP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of VRVF compared to SAP</measure>
    <time_frame>Day 1</time_frame>
    <description>Specificity of VRVF will be determined by comparing Hodapp Anderson Parrish (HAP) Scores, which assess the severity of visual field defects, to those of SAP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variability of Mean Deviation</measure>
    <time_frame>Day 1</time_frame>
    <description>Variability of the mean deviation scores obtained from VRVF and SAP</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Adults with Glaucoma or Suspected Glaucoma</arm_group_label>
    <description>Adults with Glaucoma or Suspected Glaucoma, who have previously had standard automated perimetry (SAP) and will receive virtual reality visual field (VRVF) as part of the standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Visual Field Naive Adults</arm_group_label>
    <description>Visual Field Naive Adults will receive SAP and VRVF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children with Glaucoma or Suspected Glaucoma</arm_group_label>
    <description>Children with Glaucoma or Suspected Glaucoma, who have previously had SAP and will receive VRVF as part of the standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Visual Field Naive Children</arm_group_label>
    <description>Visual Field Naive Children will receive SAP and VRVF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remote Care Arm</arm_group_label>
    <description>Glaucoma or Suspected Glaucoma participants, who have previously had SAP and will receive VRVF at their home</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Virtual Reality Visual Field</intervention_name>
    <description>A head-mounted perimeter with a wireless remote connected to a laptop that monitors responses</description>
    <arm_group_label>Adults with Glaucoma or Suspected Glaucoma</arm_group_label>
    <arm_group_label>Children with Glaucoma or Suspected Glaucoma</arm_group_label>
    <arm_group_label>Remote Care Arm</arm_group_label>
    <arm_group_label>Visual Field Naive Adults</arm_group_label>
    <arm_group_label>Visual Field Naive Children</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Standard Automated Perimetry</intervention_name>
    <description>Standard of care perimeter</description>
    <arm_group_label>Visual Field Naive Adults</arm_group_label>
    <arm_group_label>Visual Field Naive Children</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants who are glaucoma or glaucoma suspect who are being seen at Bascom Palmer Eye&#xD;
        Institute and/or healthy individuals&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          -  Any individual who is physically able to take a virtual reality visual field test&#xD;
&#xD;
          -  Patients who either have glaucoma, are glaucoma suspects, or have a strong family&#xD;
             history of glaucoma, or have other visual field defects, and normal individual&#xD;
&#xD;
          -  Age: Individuals who are old enough to comprehend the instructions and procedures&#xD;
             (1-90)&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          -  Adults unable to consent, prisoners&#xD;
&#xD;
          -  Participants who are too tired to take a visual field test&#xD;
&#xD;
          -  Participants who refuse to consent&#xD;
&#xD;
          -  Individuals who are functionally unable to use VRVF&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alana L Grajewski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hounsh Munshi, MS</last_name>
    <phone>3053266000</phone>
    <email>hxm453@miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hounsh Munshi, MS</last_name>
      <phone>305-326-6000</phone>
      <email>hxm453@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Alana L Grajewski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Alana L Grajewski</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Visual Field</keyword>
  <keyword>Virtual Reality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

